• Intelligent Bio Solutions highlighted its fingerprint-sweat drug screening system, targeting a 16-24 hour detection window to better indicate potential impairment.
• System workflow: 5-second fingertip sample collection, cartridge inserted into a reader, results in under 10 minutes.
• Validation study underway for a rapid cartridge targeting 70% faster results.
• U.S. strategy centers on seeking FDA clearance for codeine detection to expand beyond forensic-only settings into the U.S. drug screening market.
• Fiscal Q3 gross margin 50.5%; nine-month revenue USD 3.07 million; Q3 revenue USD 1.06 million; Q3 cartridge sales USD 703,538.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Intelligent Bio Solutions Inc. published the original content used to generate this news brief on June 17, 2026, and is solely responsible for the information contained therein.